David A. Siegel Cor Medix Inc. Transaction History

Two Sigma Advisers, LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$3.6 - $4.46 $136,440 - $169,034	37,900 Added 270.71%	51,900 $192,000
Q2 2023 Aug 14, 2023	SELL	$3.94 - $5.8 $136,324 - $200,680	-34,600 Reduced 71.19%	14,000 $55,000
Q1 2023 May 15, 2023	BUY	$3.22 - $4.61 $9,982 - $14,291	3,100 Added 6.81%	48,600 $201,000
Q4 2022 Feb 14, 2023	SELL	$2.81 - $4.45 $23,604 - $37,380	-8,400 Reduced 15.58%	45,500 $192,000
Q3 2022 Nov 14, 2022	SELL	$2.82 - $7.52 $104,904 - $279,744	-37,200 Reduced 40.83%	53,900 $153,000
Q2 2022 Aug 15, 2022	BUY	$2.73 - $5.61 $115,206 - $236,742	42,200 Added 86.3%	91,100 $366,000
Q1 2022 May 16, 2022	SELL	$3.83 - $6.24 $132,518 - $215,904	-34,600 Reduced 41.44%	48,900 $268,000
Q4 2021 Feb 14, 2022	SELL	$4.47 - $5.56 $337,485 - $419,779	-75,500 Reduced 47.48%	83,500 $380,000
Q3 2021 Nov 15, 2021	SELL	$4.46 - $7.11 $197,578 - $314,973	-44,300 Reduced 21.79%	159,000 $739,000
Q2 2021 Aug 16, 2021	BUY	$6.05 - $10.09 $154,880 - $258,304	25,600 Added 14.41%	203,300 $1.4 Million
Q1 2021 May 17, 2021	SELL	$6.84 - $17.58 $248,292 - $638,153	-36,300 Reduced 16.96%	177,700 $1.78 Million
Q4 2020 Feb 16, 2021	BUY	$5.0 - $9.15 $459,500 - $840,885	91,900 Added 75.27%	214,000 $1.59 Million
Q3 2020 Nov 16, 2020	BUY	$3.96 - $6.15 $428,868 - $666,045	108,300 Added 784.78%	122,100 $736,000
Q2 2020 Aug 14, 2020	BUY	$3.08 - $6.56 $42,504 - $90,528	13,800 New	13,800 $87,000

112

17.7M

134K

441K

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $464M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.